Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

(2013) A Loganayagam et al.   BRITISH JOURNAL OF CANCER

Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity

(2013) S. M. Offer et al.   CANCER RESEARCH

A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity

(2013) S M Offer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients

(2013) MH Kristensen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Dermatologic Presentations of Orthopedic Pathologies

(2012) Daniel Marchalik et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients

(2012) Barbara Büchel et al.   BIOMEDICAL CHROMATOGRAPHY

Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis

(2012) M B Garg et al.   BRITISH JOURNAL OF CANCER

Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

(2012) F. Mueller et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy

(2012) Johanna Sistonen et al.   CLINICA CHIMICA ACTA

Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma

(2012) François Coudoré et al.   JOURNAL OF CHROMATOGRAPHIC SCIENCE

Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy

(2011) Yvonne Wettergren et al.   CANCER

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

(2011) Maurice C. van Staveren et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

(2011) M. J. Deenen et al.   CLINICAL CANCER RESEARCH

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

(2011) Ursula Amstutz et al.   PHARMACOGENOMICS

A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer

(2011) Isabela Costa César et al.   THERAPEUTIC DRUG MONITORING

Circadian Timing in Cancer Treatments

(2010) Francis Lévi et al.   Annual Review of Pharmacology and Toxicology

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

(2010) André B. P. van Kuilenburg et al.   HUMAN GENETICS

Comparison of the Mantel test and alternative approaches for detecting complex multivariate relationships in the spatial analysis of genetic data

(2010) PIERRE LEGENDRE et al.   Molecular Ecology Resources

Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows

(2010) LAURENT EXCOFFIER et al.   Molecular Ecology Resources

PASSaGE: Pattern Analysis, Spatial Statistics and Geographic Exegesis. Version 2

(2010) Michael S. Rosenberg et al.   Methods in Ecology and Evolution

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy

(2009) Z. KLEIBL et al.   NEOPLASMA

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment

(2009) Ursula Amstutz et al.   PHARMACOGENOMICS

Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: A potential mechanism for benefits of 5FU chrono-chemotherapy

(2009) Kamran Abolmaali et al.   SURGERY

Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?

(2008) J. L. Yen-Revollo et al.   CLINICAL CANCER RESEARCH

HPLC with UV or Mass Spectrometric Detection for Quantifying Endogenous Uracil and Dihydrouracil in Human Plasma

(2008) R. Svobaite et al.   CLINICAL CHEMISTRY

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group

(2008) Matthias Schwab et al.   JOURNAL OF CLINICAL ONCOLOGY

The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil

(2008) R. Ben Fredj et al.   PATHOLOGIE BIOLOGIE

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients

(2008) Eva Gross et al.   PLoS One